Today announced that it offers secured yet another $10 million from current investors to support development of the company's lead compound palovarotene for the treating fibrodysplasia ossificans progressive . Led by OrbiMed Advisors with participation by BDC Venture Capital, the brand new funds bring the total amount elevated in the Series A funding to $32.5 million. ‘We appreciate the continued confidence our investors have shown in the potential of palovarotene and the improvement of our clinical program,’ stated Clarissa Desjardins, Ph.D., Chief Executive Officer of Clementia. ‘We remain focused on bringing a potential treatment option to FOP patients living with this devastating and life-threatening disease.’ Related StoriesPhase III studies show Roche's ocrelizumab reduces relapse rate, delays disability progression in MS patientsNovartis announces FDA approval of dual combination bronchodilator Utibron Neohaler for COPD patientsUCSF analysis on mood disorders aims to progress understanding and treatment of depressionPalovarotene, an investigational retinoic acid receptor gamma agonist, is currently in a Phase 2 clinical trial in patients with FOP.Supply Anthem Blue Cross in California.. Blue-collar workers with arthritis in very much even worse health than all the workers While more Americans will work past age 65 by choice, an evergrowing segment of the populace must continue to work very well to their sixties out of financial necessity. Analysis executed by the Columbia University’s Mailman College of Public Health insurance and the University of Miami Miller College of Medicine viewed aging, social course and work force participation prices to illustrate the difficulties that low income workers encounter in the global market. The study used the responsibility of arthritis to consider these connections because 49 million U.S. Adults have arthritis, and 21 million suffer activity limitations as a complete result.